Roth Capital analyst Jotin Marango maintained a Buy rating on Epizyme (NASDAQ: EPZM) today and set a price target of $18. The company’s shares opened today at $8.82, close to its 52-week low of $7.96.
According to TipRanks.com, Marango is a 1-star analyst with an average return of -0.5% and a 32.7% success rate. Marango covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Stemline Therapeutics Inc, and Cyclacel Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Epizyme with a $22.25 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $21.40 and a one-year low of $7.96. Currently, Epizyme has an average volume of 553.9K.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EPZM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Develops therapeutics for the treatment of patients with genetically defined cancers
